A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication

被引:14
作者
Johnson, Dustin L. [1 ,2 ,3 ]
Stone, Chris B. [1 ,2 ,3 ]
Bulir, David C. [1 ,2 ,3 ]
Coombes, Brian K. [1 ,2 ,3 ]
Mahony, James B. [1 ,2 ,3 ]
机构
[1] McMaster Univ, MG DeGroote Inst Infect Dis Res, Hamilton, ON L8S 4L8, Canada
[2] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada
[3] St Josephs Healthcare, Father Sean OSullivan Res Ctr, Hamilton, ON, Canada
来源
BMC MICROBIOLOGY | 2009年 / 9卷
基金
加拿大健康研究院;
关键词
ENDOMETRIAL EPITHELIAL-CELLS; SMALL-MOLECULE INHIBITOR; OUTER-MEMBRANE PROTEIN; TRACHOMATIS SEROVAR-E; CHLAMYDIA-PNEUMONIAE; III SECRETION; MULTIPLE-SCLEROSIS; IN-VITRO; 1ST-CHOICE ANTIBIOTICS; DEVELOPMENTAL CYCLE;
D O I
10.1186/1471-2180-9-218
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: We have shown previously that Chlamydophila pneumoniae contains a dual-specific Ser/Thr protein kinase that phosphorylates CdsD, a structural component of the type III secretion apparatus. To further study the role of PknD in growth and development we sought to identify a PknD inhibitor to determine whether PknD activity is required for replication. Results: Using an in vitro kinase assay we screened 80 known eukaryotic protein kinase inhibitors for activity against PknD and identified a 3'-pyridyl oxindole compound that inhibited PknD autophosphorylation and phosphorylation of CdsD. The PknD inhibitor significantly retarded the growth rate of C. pneumoniae as evidenced by the presence of very small inclusions with a reduced number of bacteria as seen by electron microscopy. These inclusions contained the normal replicative forms including elementary bodies (EB), intermediate bodies (IB) and reticulate bodies (RB), but lacked persistent bodies (PB), indicating that induction of persistence was not the cause of reduced chlamydial growth. Blind passage of C. pneumoniae grown in the presence of this PknD inhibitor for 72 or 84 hr failed to produce inclusions, suggesting this compound blocks an essential step in the production of infectious chlamydial EB. The compound was not toxic to HeLa cells, did not block activation of the MEK/ERK pathway required for chlamydial invasion and did not block intracellular replication of either Chlamydia trachomatis serovar D or Salmonella enterica sv. Typhimurium suggesting that the inhibitory effect of the compound is specific for C. pneumoniae. Conclusion: We have identified a 3'-pyridyl oxindole compound that inhibits the in vitro kinase activity of C. pneumoniae PknD and inhibits the growth and production of infectious C. pneumoniae progeny in HeLa cells. Together, these results suggest that PknD may play a key role in the developmental cycle of C. pneumoniae.
引用
收藏
页数:13
相关论文
共 59 条
[1]   Chlamydia pneumoniae arthritis in a patient with common variable immunodeficiency [J].
Ardeniz, Ö ;
Gülbahar, Ö ;
Mete, N ;
Çiçek, C ;
Basoglu, OK ;
Sin, A ;
Kokuludag, A .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2005, 94 (04) :504-508
[2]   Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle [J].
Bailey, Leslie ;
Gylfe, Asa ;
Sundin, Charlotta ;
Muschiol, Sandra ;
Elofsson, Mikael ;
Nordstrom, Peter ;
Henriques-Normark, Birgitta ;
Lugert, Raimond ;
Waldenstrom, Anders ;
Wolf-Watz, Hans ;
Bergstrom, Sven .
FEBS LETTERS, 2007, 581 (04) :587-595
[3]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[4]   The selectivity of protein kinase inhibitors: a further update [J].
Bain, Jenny ;
Plater, Lorna ;
Elliott, Matt ;
Shpiro, Natalia ;
Hastie, C. James ;
Mclauchlan, Hilary ;
Klevernic, Iva ;
Arthur, J. Simon C. ;
Alessi, Dario R. ;
Cohen, Philip .
BIOCHEMICAL JOURNAL, 2007, 408 :297-315
[5]  
Balin BJ, 2008, J ALZHEIMERS DIS, V13, P371
[6]   Frequency of spontaneous mutations that confer antibiotic resistance in Chlamydia spp. [J].
Binet, R ;
Maurelli, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2865-2873
[7]   Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C-trachomatis L2 [J].
Binet, Rachel ;
Maurelli, Anthony T. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) :4267-4275
[8]   Chlamydia pneumoniae and cardiovascular disease [J].
Campbell, LA ;
Kuo, CC ;
Grayston, JT .
EMERGING INFECTIOUS DISEASES, 1998, 4 (04) :571-579
[9]   Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis [J].
Contini, C. ;
Seraceni, S. ;
Cultrera, R. ;
Castellazzi, M. ;
Granieri, E. ;
Fainardi, E. .
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (04) :564-566
[10]   Identification of MEK- and phosphoinositide 3-kinase-dependent signalling as essential events during Chlamydia pneumoniae invasion of HEp2 cells [J].
Coombes, BK ;
Mahony, JB .
CELLULAR MICROBIOLOGY, 2002, 4 (07) :447-460